Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : All Clowns Must Be Destroyed -- Ignore unavailable to you. Want to Upgrade?

To: eddie r gammon who wrote (23558)	4/6/2000 11:00:00 AM
From: flatsville	Read Replies (1) \| Respond to of 42523

This one is for real too. siliconinvestor.com Zadaxin is gonna make this co. a fortune. Promising immunomodulator for a wide variety of applications. Virtually no negative side effects discovered to date. A biotech with earnings about to go positive. What a concept... >>>DTIC therapy significantly depresses a patient's immune system. In the study, ZADAXIN significantly improved the patients' immune system by restoring their natural killer (NK) cells and helper T-cells (CD4), both of which are disease fighting white blood cells. "We believe ZADAXIN immunotherapy will be a key component of multiple drug treatments for numerous cancers, infectious diseases and immune system disorders," said Donald R. Sellers, SciClone's President and Chief Executive Officer. "This study, in addition to a prior pilot phase 2 metastatic malignant melanoma study, several preclinical cancer studies, recent mechanism of action studies and our long experience in treating hepatitis patients, all validate that belief. We expect malignant melanoma to be a major focus of our new U.S. cancer program." No proven life-prolonging therapy exists for metastatic malignant melanoma, the leading cause of skin cancer death. Approximately 44,000 new cases are diagnosed each year in the U.S. and 7,300 deaths are reported. The response rate with the current drug of choice, DTIC, is approximately 20% and is usually of short duration with little impact on survival. Many patients with cancer and chronic infectious diseases have an impaired immune system. ZADAXIN significantly enhances the immune system's ability to recognize and destroy cancerous and infected cells. ZADAXIN may be a key component in the growing trend toward multiple drug cocktails for cancer and infectious diseases. ZADAXIN immunotherapy is in late-stage development for cancer and viral hepatitis worldwide. ZADAXIN now is approved for marketing in 19 countries, principally for treatment of hepatitis B and hepatitis C. SciClone has filed for ZADAXIN marketing approval in 18 additional countries...<<<